FY2030 Earnings Forecast for PVLA Issued By HC Wainwright

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Palvella Therapeutics in a research report issued to clients and investors on Monday, February 9th. HC Wainwright analyst A. Fein expects that the company will earn $7.05 per share for the year. HC Wainwright has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Several other research firms have also commented on PVLA. Truist Financial boosted their price objective on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Mizuho assumed coverage on Palvella Therapeutics in a research report on Wednesday, January 7th. They set an “outperform” rating and a $205.00 price objective for the company. Finally, Oppenheimer reissued an “outperform” rating and issued a $200.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $158.69.

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $81.01 on Tuesday. The firm’s 50-day moving average price is $94.14 and its 200-day moving average price is $75.15. The company has a market capitalization of $959.16 million, a PE ratio of -30.80 and a beta of -0.16. Palvella Therapeutics has a 1-year low of $14.68 and a 1-year high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Archer Investment Corp bought a new position in shares of Palvella Therapeutics during the 3rd quarter valued at $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in Palvella Therapeutics in the second quarter valued at about $37,000. JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 12,906 shares of company stock valued at $1,205,980. Corporate insiders own 20.50% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.